Special Issue "Drug Resistance in Cancers"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (1 July 2018)
Prof. Zhixiang Wang
Signal Transduction Research Group, Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
Website | E-Mail
Interests: ErbB receptors; cell signaling; protein trafficking; breast cancer; small GTPases and cell cycle
Cancer is among the leading causes of mortality in Canada. Despite advances in treatment in all settings, disease recurrence and progression remains a major obstacle to therapy. One of the main clinical issues is the development of drug resistance. Drug resistance exists in two forms: Acquired resistance, where the drug is initially efficient but becomes ineffective over time, while intrinsic resistance occurs when a drug is ineffective from the beginning of treatment. The hallmarks of drug resistance in cancers include sustained tumor cell proliferation, insensitive to growth suppressors, resisting cell death, and active invasion. The most established in vitro mechanism for resistance to more than one chemically unrelated class of agents (multidrug resistance) is the overexpression of drug efflux proteins, such as ATP-binding cassette. Resistances may also arise that are specific to one group of drugs. In general, drug resistance could arise due to decreased intracellular drug concentrations, alterations of drug targets, epigenetic modification, and activation of certain signaling cascades. Many strategies have been developed to combat drug resistance, including sequential therapy and combination therapy, immunotherapy and targeted therapy. Understanding the mechanisms underlying drug resistance and the development of novel therapies are key to overcoming drug resistance.
Prof. Dr. Zhixiang Wang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug resistance
- multidrug resistance
- intrinsic drug resistance
- acquired drug resistance
- disease recurrence
- targeted therapy